An estimate of prostate cancer prevalence for a demographically similar workforce population.
To obtain an estimate of prostate cancer prevalence when screening is applied to a workforce, we conducted a search of the English world literature from West Virginia University. Thirty-one papers which met selection criteria for screening were followed by histopathologic diagnosis. Publications using Prostate Specific Antigen (PSA) as a screening test were reviewed. The data from these papers were combined. Population characteristics were then selected to represent the demographics of a working population. Prostate cancer prevalence estimates for the demographics of a working population were calculated using a weighted mean after relevant studies lacked homogeneity and therefore failed meta-analysis. The expected prevalence of prostate cancer in a workplace surveillance population is 2.03% (95% C.I. from 1.69% to 2.37%). This information is useful to entities considering workplace surveillance. Selection bias, geographic location, and uncertainty in prediction of a representative workforce population may strongly influence estimates.
Westra
C S
CS
Kimberly Clark Corporation, Neenah, Wisc., USA.
Ducatman
A M
AM
Niewiadomska-Bugaj
M
M
Hobbs
G R
GR
D000368:Aged; D002170:Canada; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D009786:Occupational Health Services / Q000191:economics; D017410:Practice Guidelines as Topic; D015995:Prevalence; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D014481:United States
D017430:Prostate-Specific Antigen